100 related articles for article (PubMed ID: 6135909)
1. Treatment of advanced prostatic cancer with LHRH analogue ICI 118630: clinical response and hormonal mechanisms.
Ahmed SR; Brooman PJ; Shalet SM; Howell A; Blacklock NJ; Rickards D
Lancet; 1983 Aug; 2(8347):415-9. PubMed ID: 6135909
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of the LHRH agonist, ICI 118630, in the treatment of advanced prostatic carcinoma.
Walker KJ; Nicholson RI; Turkes AO; Turkes A; Griffiths K; Robinson M; Crispin Z; Dris S
Lancet; 1983 Aug; 2(8347):413-5. PubMed ID: 6135908
[TBL] [Abstract][Full Text] [Related]
3. Prostatic cancer: treatment with long-acting LHRH analogue.
Williams G; Allen JM; O'Shea JP; Mashiter K; Doble A; Bloom SR
Br J Urol; 1983 Dec; 55(6):743-6. PubMed ID: 6228283
[TBL] [Abstract][Full Text] [Related]
4. Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer.
Ahmed SR; Grant J; Shalet SM; Howell A; Chowdhury SD; Weatherson T; Blacklock NJ
Br Med J (Clin Res Ed); 1985 Jan; 290(6463):185-7. PubMed ID: 3155636
[TBL] [Abstract][Full Text] [Related]
5. Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer--speculations about possible role of the monoamine system.
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević Z
Neoplasma; 1997; 44(5):308-13. PubMed ID: 9473791
[TBL] [Abstract][Full Text] [Related]
6. Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist.
Allen JM; O'Shea JP; Mashiter K; Williams G; Bloom SR
Br Med J (Clin Res Ed); 1983 May; 286(6378):1607-9. PubMed ID: 6221774
[TBL] [Abstract][Full Text] [Related]
7. The treatment of metastatic prostatic cancer with the slow release LH-RH analogue Zoladex ICI 118630.
Beacock CJ; Buck AC; Zwinck R; Peeling WB; Rees RW; Turkes A; Walker K; Griffiths K
Br J Urol; 1987 May; 59(5):436-42. PubMed ID: 2954605
[TBL] [Abstract][Full Text] [Related]
8. Luteinizing hormone-releasing hormone (LHRH) agonists for treatment of advanced prostatic carcinoma.
Chodak GW
Urology; 1989 May; 33(5 Suppl):42-4. PubMed ID: 2523610
[TBL] [Abstract][Full Text] [Related]
9. Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?
Pickles T; Hamm J; Morris WJ; Schreiber WE; Tyldesley S
BJU Int; 2012 Dec; 110(11 Pt B):E500-7. PubMed ID: 22564197
[TBL] [Abstract][Full Text] [Related]
10. Randomised controlled study of orchidectomy vs long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma.
Parmar H; Phillips RH; Lightman SL; Edwards L; Allen L; Schally AV
Lancet; 1985 Nov; 2(8466):1201-5. PubMed ID: 2866289
[TBL] [Abstract][Full Text] [Related]
11. Treatment of prostatic cancer with a depot form of a luteinizing hormone-releasing hormone analogue.
Giuliani L; Barreca T; Giberti C; Franceschini R; Martorana G; Brancadoro MT; Salvemini M; Rolandi E
Eur Urol; 1986; 12(6):390-4. PubMed ID: 2949979
[TBL] [Abstract][Full Text] [Related]
12. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
13. Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone.
Kerle D; Williams G; Ware H; Bloom SR
Br Med J (Clin Res Ed); 1984 Aug; 289(6443):468-9. PubMed ID: 6235888
[No Abstract] [Full Text] [Related]
14. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
Kuber W; Treu T; Kratzik C; Girsch E; Zeillinger R; Spona J
Wien Klin Wochenschr; 1990 Nov; 102(21):640-7. PubMed ID: 2148044
[TBL] [Abstract][Full Text] [Related]
15. The treatment of metastatic prostatic cancer with a potent luteinizing hormone releasing hormone analogue.
Trachtenberg J
J Urol; 1983 Jun; 129(6):1149-52. PubMed ID: 6406688
[TBL] [Abstract][Full Text] [Related]
16. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.
Bong GW; Clarke HS; Hancock WC; Keane TE
Urology; 2008 Jun; 71(6):1177-80. PubMed ID: 18279929
[TBL] [Abstract][Full Text] [Related]
17. Sustained suppression of testosterone production by the luteinising-hormone releasing-hormone agonist buserelin in patients with advanced prostate carcinoma. A new therapeutic approach?
Borgmann V; Hardt W; Schmidt-Gollwitzer M; Adenauer H; Nagel R
Lancet; 1982 May; 1(8281):1097-9. PubMed ID: 6122893
[TBL] [Abstract][Full Text] [Related]
18. Experience with an LHRH analogue in the management of relapsed progressive prostatic cancer.
Kerle D; Williams G; Ware H; Doble A; Allen J; Bloom SR
Br J Urol; 1984 Oct; 56(5):495-8. PubMed ID: 6242022
[TBL] [Abstract][Full Text] [Related]
19. A new hormonal therapy for prostatic cancer: long-term clinical and hormonal response.
Ahmed SR; Grant JB; Shalet SM; Howell A; Costello CB; Weatherson T; Blacklock NJ
Br J Urol; 1986 Oct; 58(5):534-8. PubMed ID: 2946355
[TBL] [Abstract][Full Text] [Related]
20. Recovery of Serum Testosterone Levels and Sexual Function in Patients Treated With Short-term Luteinizing Hormone-releasing Hormone Antagonist as a Neoadjuvant Therapy Before External Radiotherapy for Intermediate-risk Prostate Cancer: Preliminary Prospective Study.
Inoue T; Mizowaki T; Kabata D; Shintani A; Terada N; Yamasaki T; Negoro H; Kobayashi T; Nakamura K; Inokuchi H; Ogawa O
Clin Genitourin Cancer; 2018 Apr; 16(2):135-141.e1. PubMed ID: 29051056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
